Biovitrum Appoints The Bank of New York Mellon as Depositary Bank>
Biovitrum Appoints The Bank of New York Mellon as Depositary Bank
(Thomson Reuters ONE) - STOCKHOLM - July 7, 2009 - Biovitrum AB (publ) (STO: BVT) hasselected The Bank of New York Mellon (NYSE: BK), as the depositarybank for its Level I American depositary receipt (ADR) program. EachBiovitrum ADR represents one common share and trades on theover-the-counter market. The common shares trade on the Stockholm OMXNordic Exchange under the symbol "BVT.""We are very happy with the agreement with The Bank of New YorkMellon as it has a strong and proven track record," said MartinNicklasson, CEO of Biovitrum. "We wish to optimize U.S. investoraccess to our share, and we believe the Bank has the resources andexpertise necessary to help us achieve that goal.""We look forward to helping Biovitrum unlock the potential of theU.S. capital markets," said Michael Cole-Fontayn, chief executiveofficer of The Bank of New York Mellon's Depositary Receipt Division."As the world's leading depositary, The Bank of New York Mellon willutilize its resources to develop a long and mutually beneficialpartnership with Biovitrum and its investors."About BiovitrumBiovitrum is an international pharmaceutical company that marketsspecialist pharmaceuticals in several regions. Using its expertiseand experience Biovitrum takes scientific innovation to patients withsignificant unmet medical need. Research expertise and capabilitiesare focused on development and production of biotechnologytherapeutics within our prioritized areas of hemophilia,inflammation/autoimmune diseases, cancer supportive care andmalabsorption. The company has revenues of approximately SEK 1.2billion and around 400 employees. The company head office is locatedin Sweden and it is listed on the Stockholm OMX Nordic Exchange. Formore information please visit www.biovitrum.comAbout Bank of New York MellonThe Bank of New York Mellon acts as depositary for more than 2,100American and global depositary receipt programs, acting inpartnership with leading companies from 67 countries. With anunrivalled commitment to helping securities issuers succeed in theworld's rapidly evolving financial markets, the Company delivers theindustry's most comprehensive suite of integrated depositary receipt,corporate trust and stock transfer services. Additional informationis available at www.bnymellon.com/dr.For more information please contact:BiovitrumMartin Nicklasson, CEOPhone: +46 8 697 2545Göran Arvidson, CFOCell phone: +46 70 633 30 42Erik Kinnman, VP Investor RelationsCell phone: +46 73 422 15 40erik.kinnman(at)biovitrum.comBiovitrum AB (publ) may be required to disclose the informationprovided herein pursuant to the Swedish Securities Markets Act. Theinformation was provided for public release on July 7, 2009 at 3.00p.m. CET.http://hugin.info/134557/R/1327570/312783.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
" alt="Talvivaara Mining Company Plc Directors Dealings>">
" alt="Staffordshire Police Selects EpiForce(R) Security Solution>">
Datum: 07.07.2009 - 15:00 Uhr
Sprache: Deutsch
News-ID 3321
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 937 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biovitrum Appoints The Bank of New York Mellon as Depositary Bank>"
steht unter der journalistisch-redaktionellen Verantwortung von
Biovitrum (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
